跳至主要内容
临床试验/NCT01198912
NCT01198912已完成2 期

Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial.

University Hospital, Ghent2 个研究点 分布在 2 个国家目标入组 33 人开始时间: 2011年11月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
33
试验地点
2
主要终点
Endoscopic evaluation of quality and speed of wound healing

研究概览

简要总结

This is a randomized, double blind, placebo controlled, parallel group, study in patients with chronic rhinosinusitis with or without nasal polyps. The objective is to test the clinical efficacy of long-term low dose oral doxycycline on wound healing quality after endoscopic sinus surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • at least 18 years of age, of either sex and any race
  • diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the EPOS guidelines research
  • Subjects should be regularly scheduled for bilateral functional endonasal endoscopic sinus surgery
  • Subjects must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures or compromise his/her safety.
  • Subjects must be willing to give informed consent and adhere to visit schedules, medication restrictions, and agree to perform daily diary entries.
  • Nonpregnant women of childbearing potential must use a medically acceptable, adequate form of birth control.

排除标准

  • Women must not be pregnant, breast feeding, or premenarcheal.
  • Subjects who have required oral corticosteroids within the previous four weeks prior to surgery.
  • Subjects who have required nasal corticosteroids within the previous one week prior to surgery.
  • Subjects with known allergic reaction on tetracyclines, diabetes (type 1 and 2), renal insufficiency, severe liver disease, systemic diseases affecting the nose (e.g. M. Wegener), prior surgeries of the paranasal sinuses.
  • Patients with the following diseases should be excluded :
  • Cystic fibrosis based on positive sweat test or DNA alleles
  • Gross immunodeficiency (congenital or acquired)
  • congenital mucociliary problems e.g. primary ciliary dyskinesia (PCD)
  • Non-invasive fungal balls and invasive fungal disease
  • systemic vasculitis and granulomatous diseases
  • Cocaine abuse

研究组 & 干预措施

placebo

Placebo Comparator

干预措施: placebo (Drug)

doxycycline 100 mg

Experimental

干预措施: doxycycline 100 mg (Drug)

结局指标

主要结局

Endoscopic evaluation of quality and speed of wound healing

时间窗: at 3 months after first drug intake

Recurrence of nasal polyps

时间窗: at 6 months after first drug intake

次要结局

  • nasal and exhaled NO(at 6 months after first drug intake)
  • inflammatory mediators in nasal fluid as well as in serum(at 6 months after first drug intake)
  • subjective assessment of the wound healing(at 6 months after first drug intake)
  • chronic rhinosinusitis symptoms by the patients(at 6 months after first drug intake)
  • Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire(at 6 months after first drug intake)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验